Search results
Results from the WOW.Com Content Network
Carbonic anhydrase inhibitors are a class of pharmaceuticals that suppress the activity of carbonic anhydrase. Their clinical use has been established as anti- glaucoma agents, diuretics , antiepileptics , in the management of mountain sickness , gastric and duodenal ulcers , idiopathic intracranial hypertension , neurological disorders , or ...
These patients, who are treated with apraclonidine to delay surgery, should have frequent follow-up examinations and treatment should be discontinued if the intraocular pressure rises significantly. Apraclonidine may be useful in the diagnosis of Horner's syndrome. In Horner's syndrome, the sympathetic innervation to the pupillary dilator ...
Glaucoma medication is divided into groups based on chemical structure and pharmacologic action. The goal of currently available glaucoma therapy is to preserve visual function by lowering intraocular pressure (IOP) in patients that have an increased intraocular pressure.
Dorzolamide/timolol, sold under the brand name Cosopt among others, is a medication used to treat high pressure inside the eye including glaucoma. [3] [5] [6] It is a combination of dorzolamide hydrochloride and timolol maleate. [3] It may be used when a beta blocker, like timolol, is not sufficient alone. [7] It is used as an eye drop. [3]
Dorzolamide is used to lower excessive intraocular pressure in open-angle glaucoma and ocular hypertension.This drug is able to cross the cornea, reach the ciliary body of the eye, and produce systemic effects on the carbonic anhydrase enzyme within the eye.
Acetazolamide is a carbonic anhydrase inhibitor, hence causing the accumulation of carbonic acid. [12] Carbonic anhydrase is an enzyme found in red blood cells and many other tissues that catalyses the following reaction: [26] H 2 CO 3 ⇌ H 2 O + CO 2. hence lowering blood pH, by means of the following reaction that carbonic acid undergoes: [27]
Inhibition of carbonic anhydrase in the ciliary processes of the eye decreases aqueous humor secretion and thus lowers the intraocular pressure in the anterior chamber, presumably by reducing the rate of formation of bicarbonate ions with subsequent reduction in sodium and fluid transport; this may alleviate the effects of open-angle glaucoma.
Netarsudil, sold under the brand name Rhopressa among others, is a medication for the treatment of glaucoma. [1] [2] [3] In the United States, in December 2017, the Food and Drug Administration (FDA) approved a 0.02% ophthalmic solution for the lowering of elevated intraocular pressure in people with open-angle glaucoma or ocular hypertension.